Global and Country-Level Analysis of Liver Cancer: Disease Burden and Recent Trends

Abstract

Background

Liver cancer is the sixth most prevalent cancer globally and the third leading cause of cancer-related mortality, with more than three-quarters of a million deaths. This has presented a significant challenge and imposed considerable strain on global public health systems. Therefore, evaluating the updated global burden of liver cancer and its recent trends in incidence and mortality is highly important, as it provides valuable insights for shaping public health policies and improving clinical practices.

Methods

The data in our article were obtained from the Global Burden of Disease Study 2021 (GBD 2021), which is available at https://vizhub.healthdata.org/gbd-results/. In this study, liver cancer mortality and incidence were estimated via the cause of death ensemble (CODEm) model for every combination of sex, age, location, and year. The incidence was modelled with DisMod-MR 2.1, a Bayesian meta-regression tool. A linear regression model was employed to explore the temporal trend of these rates, formulated as y = α + βx + ε, where x represents the calendar year and y signifies the natural logarithm of the rate. For both incidence and mortality, the estimated annual percentage change (EAPC) was computed via the formula 100 × (e^β − 1), accompanied by a 95% confidence interval (CI).

Results

First, 529,000 cases were newly diagnosed, with an age-standardized incidence rate (ASIR) of 6.15 per 100,000 people. In terms of etiology, the incidence of liver cancer caused by metabolic factors has tended to increase. Additionally, the incidence of liver cancer was greater in males and older populations. Several specific regions presented liver cancer burdens that overwhelmingly surpassed the expected age-standardized rates (ASRs) each year from 1990 to 2021, regardless of their respective sociodemographic index (SDI) scores.

Conclusion

Our findings reveal that liver cancer continues to pose a significant public health challenge. These findings suggest that targeted interventions are needed to address both the infectious and non-infectious drivers of liver cancer in different socioeconomic settings. Hence, continued efforts in prevention through vaccination, antiviral therapies, and strategies to combat metabolic diseases are crucial for reducing the global burden of liver cancer in the coming decades.

Keywords

Epidemiology / Global burden of disease / Liver cancer / Public health

References

[1] BrayF, LaversanneM, SungH, et al.. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin., 2024, 74(3): 229-263.

[2] ChenS, CaoZ, PrettnerK, et al.. Estimates and Projections of the Global Economic Cost of 29 Cancers in 204 Countries and Territories From 2020 to 2050. JAMA Oncol., 2023, 9(4): 465-472.

[3] WangM, LiuJ, YanL, et al.. Burden of liver cancer attributable to high fasting plasma glucose: a global analysis based on the global burden of disease study 2019. J Nutr Health Aging., 2024, 286. 100261

[4] JemalA, CenterMM, DeSantisC, et al.. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev., 2010, 19(8): 1893-1907.

[5] KelleyRK, GretenTF. Hepatocellular Carcinoma - Origins and Outcomes. N Engl J Med., 2021, 385(3): 280-282.

[6] SiaD, VillanuevaA, FriedmanSL, et al.. Liver Cancer Cell of Origin, Molecular Class, and Effects on Patient Prognosis. Gastroenterology., 2017, 152(4): 745-761.

[7] ZhengR, QuC, ZhangS, et al.. Liver cancer incidence and mortality in China: Temporal trends and projections to 2030. Chin J Cancer Res., 2018, 30(6): 571-579.

[8] PoonD, AndersonBO, ChenLT, et al.. Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2009. Lancet Oncol., 2009, 10(11): 1111-1118.

[9] de MartelC, Maucort-BoulchD, PlummerM, et al.. World-wide relative contribution of hepatitis B and C viruses in hepatocellular carcinoma. Hepatology., 2015, 62(4): 1190-1200.

[10] HuangJ, LokV, NgaiCH, et al.. Disease Burden, Risk Factors, and Recent Trends of Liver Cancer: A Global Country-Level Analysis. Liver Cancer., 2021, 10(4): 330-345.

[11] PangJ, ChenK, ChenS, et al.. Global burden of nonalcoholic steatohepatitis-related liver cancer, 1990–2019: a systematic analysis for the GBD 2019. Diabetol Metab Syndr., 2022, 141112.

[12] Collaborators GDaI. Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021 Lancet. 2024.

[13] WuZ, XiaF, WangW, et al.. Worldwide burden of liver cancer across childhood and adolescence, 2000–2021: a systematic analysis of the Global Burden of Disease Study 2021. EClinicalMedicine., 2024, 75. 102765

[14] Hu J, Zhou R, Ding R, et al. Effect of PM(2.5) air pollution on the global burden of lower respiratory infections, 1990–2019: A systematic analysis from the Global Burden of Disease Study 2019. J Hazard Mater. 2023;459:132215.

[15] Jessica L, Braunlin M, Laversanne M, et al. McGlynn1. International trends in liver cancer incidence, overall and by histologic subtype, 1978–2007. Int J Cancer. 2016;139(7):1534–1545

[16] WongMC, JiangJY, GogginsWB, et al.. International incidence and mortality trends of liver cancer: a global profile. Sci Rep., 2017, 745846.

[17] LiuY, ZhengJ, HaoJ, et al.. Global burden of primary liver cancer by five etiologies and global prediction by 2035 based on global burden of disease study 2019. Cancer Med., 2022, 11(5): 1310-1323.

[18] WangFS, FanJG, ZhangZ, et al.. The global burden of liver disease: the major impact of China. Hepatology., 2014, 60(6): 2099-2108.

[19] ChiangCJ, YangYW, YouSL, et al.. Thirty-year outcomes of the national hepatitis B immunization program in Taiwan. JAMA., 2013, 310(9): 974-976.

[20] CuiF, ShenL, LiL, et al.. Prevention of Chronic Hepatitis B after 3 Decades of Escalating Vaccination Policy. China. Emerg Infect Dis., 2017, 23(5): 765-772.

[21] SorianoV, LabargaP, Fernandez-MonteroJV, et al.. Hepatitis C cure with antiviral therapy–benefits beyond the liver. Antivir Ther., 2016, 21(1): 1-8.

[22] MoonAM, SingalAG, TapperEB. Contemporary Epidemiology of Chronic Liver Disease and Cirrhosis. Clin Gastroenterol Hepatol., 2020, 18(12): 2650-2666.

[23] Vitale A, Svegliati-Baroni G, Ortolani A, et al. Epidemiological trends and trajectories of MAFLD-associated hepatocellular carcinoma 2002–2033: the ITA.LI.CA database. Gut. 2023;72(1):141–152.

[24] WhiteDL, KanwalF, El-SeragHB. Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. Clin Gastroenterol Hepatol., 2012, 10(12): 1342-1359.e2.

[25] AdamsLA, LympJF, St SauverJ, et al.. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology., 2005, 129(1): 113-121.

[26] HirodeG, WongRJ. Trends in the Prevalence of Metabolic Syndrome in the United States, 2011–2016. JAMA., 2020, 323(24): 2526-2528.

[27] GorskiMT, RobertoCA. Public health policies to encourage healthy eating habits: recent perspectives. J Healthc Leadersh., 2015, 7: 81-90

[28] PerumpailBJ, KhanMA, YooER, et al.. Clinical epidemiology and disease burden of nonalcoholic fatty liver disease. World J Gastroenterol., 2017, 23(47): 8263-8276.

[29] Berkan-KawinskaA, PiekarskaA. Hepatocellular carcinoma in non-alcohol fatty liver disease - changing trends and specific challenges. Curr Med Res Opin., 2020, 36(2): 235-243.

[30] AkinyemijuT, AberaS, AhmedM, et al.. The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level: Results From the Global Burden of Disease Study 2015. JAMA Oncol., 2017, 3(12): 1683-1691.

[31] LiuZ, JiangY, YuanH, et al.. The trends in incidence of primary liver cancer caused by specific etiologies: Results from the Global Burden of Disease Study 2016 and implications for liver cancer prevention. J Hepatol., 2019, 70(4): 674-683.

[32] ChenT, ZhangY, LiuJ, et al.. Trends in liver cancer mortality in China from 1990 to 2019: a systematic analysis based on the Global Burden of Disease Study 2019. BMJ Open., 2023, 1312. e074348

[33] WongMCS, HuangJ. The growing burden of liver cirrhosis: implications for preventive measures. Hepatol Int., 2018, 12(3): 201-203.

Funding

National Natural Science Foundation of China(No. 82073095)

National Social Science Fund of China(20BTY029)

medical Sci-Tech innovation platform Foundation of Zhongnan Hospital, Wuhan University(No. PTXM2023005)

RIGHTS & PERMISSIONS

The Author(s), under exclusive licence to Huazhong University of Science and Technology